First Author: A.Ozkaya TURKEY
Co Author(s): Z. Alkin I. Perente K. Yuksel O. Baz C. Alagoz A.T. Yazici 0 0 0 0 0 0 0 0 0
Back to previous
To compare the efficacy of intravitreal bevacizumab (IVB) for the treatment of neovascular age-related macular degeneration (nAMD) between phakic and pseudophakic eyes.
Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
The newly diagnosed nAMD patients were included in this retrospective study. The patients were divided into phakic and pseudophakic groups. Initially the patients received 3 consecutive monthly IVB injections, and then the treatment was continued on an as-needed regimen. Patients were examined monthly, and the data at baseline, month 3, 6, 9, 12 and at the last follow-up were evaluated. The changes in VA, central retinal thickness (CRT), and the number of injections were compared between the two groups.
The study included 62 eyes of 62 patients (39 phakic, and 23 pseudophakic patients). Mean follow-up time was 19.7, and 17.2 months in the phakic, and pseudophakic groups, respectively (p=0.06). Mean LogMAR VA at the baseline, month 12 and the last follow-up was 0.82, 0.72, and 0.75, in the phakic group; and 0.77, 0.67, and 0.68 in the pseudophakic group, respectively. The change in mean BCVA from the baseline to month 12, and at the last follow-up was not statistically different between the two groups (p=0.9, and p=0.7 respectively). Mean injection number at month 12 was 4.5 and 4.9 in the phakic and pseudophakic group, respectively (p=0.2).
The beneficial effect of IVB is equal in both of the phakic and pseudophakic group of nAMD patients. The functional and anatomical outcomes of the treatment, and the number of injections were similar in the two groups.